News – Page 6 – Alligator Bioscience

2023-10-31

Alligator Bioscience Announces Capital Markets Day 2023

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces it will hold a Capital Markets Day on December 1, 2023. ...

2023-10-26

Regulatory

European Medicines Agency grants mitazalimab Orphan Designation in pancreatic cancer Technical Feasibility achieved in second collaboration ...

2023-10-12

New patent expands protection for mitazalimab in Europe Patent protects composition of matter for mitazalimab until 2038 (including potentia ...

2023-10-05

ATOR-1017, a potential best-in-class 4-1BB monoclonal antibody, demonstrates an excellent preclinical profile with a unique binding site on ...

2023-10-03

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the fo ...

2023-09-29

Regulatory

During September 2023, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the exercise of ...

2023-09-28

Clinical and preclinical data from three presentations further demonstrate mitazalimab's ability to activate the immune system and enha ...

2023-09-27

Data demonstrate that mitazalimab induces transcriptomic alterations consistent with immune activation Data reinforce mitazalimab's mod ...

2023-09-01

The exercise period for warrants series TO 6 in Alligator Bioscience AB (publ) (“Alligator” or the “Company”) ended on 31 August 2023. A tot ...